Are you over 18 and want to see adult content?
More Annotations
![A complete backup of https://reviewbox.es](https://www.archivebay.com/archive6/images/9cf1039c-6fa7-42f3-94f9-30584e657309.png)
A complete backup of https://reviewbox.es
Are you over 18 and want to see adult content?
![A complete backup of https://lehren.com](https://www.archivebay.com/archive6/images/2630a2bf-f2b4-4133-97e5-c9eaa0162d93.png)
A complete backup of https://lehren.com
Are you over 18 and want to see adult content?
![A complete backup of https://instituteofnext.com](https://www.archivebay.com/archive6/images/91959119-fcea-481d-8c02-5fce55a40534.png)
A complete backup of https://instituteofnext.com
Are you over 18 and want to see adult content?
![A complete backup of https://debouchage-debouchetout.fr](https://www.archivebay.com/archive6/images/6b889bed-d3ca-4afd-8da1-6d270de00b96.png)
A complete backup of https://debouchage-debouchetout.fr
Are you over 18 and want to see adult content?
![A complete backup of https://standardconcessionsupply.com](https://www.archivebay.com/archive6/images/85792519-f4c8-4630-b003-481788189d36.png)
A complete backup of https://standardconcessionsupply.com
Are you over 18 and want to see adult content?
![A complete backup of https://publiclawforeveryone.com](https://www.archivebay.com/archive6/images/10c804fe-f3cd-4a05-abce-8dea28760edc.png)
A complete backup of https://publiclawforeveryone.com
Are you over 18 and want to see adult content?
![A complete backup of https://joinup.ua](https://www.archivebay.com/archive6/images/628991c0-ed89-471e-8e31-d892c7f315d1.png)
A complete backup of https://joinup.ua
Are you over 18 and want to see adult content?
![A complete backup of https://youniversitytv.com](https://www.archivebay.com/archive6/images/cf12515d-7e62-4e57-b5bf-8a3449479293.png)
A complete backup of https://youniversitytv.com
Are you over 18 and want to see adult content?
![A complete backup of https://tuugo.co.nz](https://www.archivebay.com/archive6/images/dcdc349e-2641-4ec9-8a94-32f691c34f81.png)
A complete backup of https://tuugo.co.nz
Are you over 18 and want to see adult content?
![A complete backup of https://horizonpower.com.au](https://www.archivebay.com/archive6/images/cd02fcea-2aec-4f97-89dc-a3ebacbee61f.png)
A complete backup of https://horizonpower.com.au
Are you over 18 and want to see adult content?
![A complete backup of https://dallasweekly.com](https://www.archivebay.com/archive6/images/c715cd87-300d-4954-96d7-4c2e6df86973.png)
A complete backup of https://dallasweekly.com
Are you over 18 and want to see adult content?
Favourite Annotations
![A complete backup of all-andorra.blogspot.com](https://www.archivebay.com/archive2/a20bbbf1-bf68-452b-9340-3ec2608f80af.png)
A complete backup of all-andorra.blogspot.com
Are you over 18 and want to see adult content?
![A complete backup of miyamoto-unosuke.co.jp](https://www.archivebay.com/archive2/0da40c59-8cac-4fe3-8955-054fdafdd99a.png)
A complete backup of miyamoto-unosuke.co.jp
Are you over 18 and want to see adult content?
![A complete backup of nuevoysurbeachclub.com](https://www.archivebay.com/archive2/38195117-6d7d-4d0a-9aa7-53b26ad9f88d.png)
A complete backup of nuevoysurbeachclub.com
Are you over 18 and want to see adult content?
![A complete backup of greeninstruments.com](https://www.archivebay.com/archive2/9ecd6234-3a98-4b09-8bde-6d74d04c4f66.png)
A complete backup of greeninstruments.com
Are you over 18 and want to see adult content?
![A complete backup of hisarcityinfo.com](https://www.archivebay.com/archive2/e9d03f6c-67a1-42a4-b7ba-6d79a25f69d7.png)
A complete backup of hisarcityinfo.com
Are you over 18 and want to see adult content?
Text
company.
AN EVALUATION OF EMPIRIC TREATMENT PATTERNS FOR ADULT An Evaluation of Empiric Treatment Patterns for Adult Patients with Community-Onset “Low-Risk” Complicated Intra-Abdominal InfectionsAcross US Hospitals
POSTER #1844 ERAVACYCLINE IS ACTIVE AGAINST CARBAPENEM Eravacycline is Active against Carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii Isolates in the FDA-CDC Antimicrobial Resistance Isolate Bank Panels Corey Fyfe, Gabrielle LeBlanc, Joyce A. Sutcliffe, Trudy H. Grossman PHARMACOKINETICS-PHARMACODYNAMICS OF EFFICACY FOR Brian D. VanScoy, B.S. Institute for Clinical Pharmacodynamics, Inc. 242 Broadway Schenectady, NY 12305 Telephone: (518) 631-8100 Fax:(518) 631-8199
POSTER # EFFICACY OF ERAVACYCLINE IN OBESE PATIENTS Efficacy of Eravacycline in Obese Patients: Pooled Analysis of IGNITE1 and IGNITE4 Allyson Fonte, Steven Kolkin, Kenneth Lawrence, SergeyIzmailyan
SUN-332 TP-6076, A FULLY SYNTHETIC TETRACYCLINE TP-6076, A Fully Synthetic Tetracycline Antibacterial Agent, Is Highly Potent against a Broad Range of Pathogens, including Carbapenem-resistant Enterobacteriaceae C MULTICENTER EVALUATION OF ERAVACYCLINE MIC RESULTS FOR Study Design: MicroScan Dried Gram Negative MIC panels were tested concurrently with a CLSI frozen broth microdilution reference panel atthree sites using
TPHASE.COM - TETRAPHASEABOUTSCIENCEPRODUCTSPEOPLE AND CULTURECONTACTCOMPLIANCE A CRITICAL MISSION TO SAVE MILLIONS AT RISK. Tetraphase is fighting one of the most significant threats to humanity — antibiotic resistance — through the promise of our technology and the passion of our people. We are committed to making novel antibiotics accessible to all patients in need. Learn More. TETRAPHASE » OUR COMPANY Our Company. Committed to a Brighter Outlook. According to The Review on Antimicrobial Resistance (May 2016), by 2050, antimicrobial resistance is projected to kill more people than cancer and diabetes combined. At Tetraphase, the fight against antimicrobial resistance is TETRAPHASE » CONTACT US We are committed to providing the most current, accurate, and balanced scientific information on Tetraphase products in response to your unsolicited requests. Contact us directly: If in the US, call 1-833-7-XERAVA (1-833-793-7282), send an email to tphasemedinfo@ljpc.com, or complete the form below. If outside the US, send an email to medinfo TETRAPHASE » LEADERSHIP Guy Macdonald has served as a member of our board of directors since January 2008, in addition to serving as our President and Chief Executive Officer from January 2008 to August 2019. From August 2003 until January 2008, Mr. Macdonald served as Executive Vice President, Operations of Idenix Pharmaceuticals, Inc., a biopharmaceuticalcompany.
AN EVALUATION OF EMPIRIC TREATMENT PATTERNS FOR ADULT An Evaluation of Empiric Treatment Patterns for Adult Patients with Community-Onset “Low-Risk” Complicated Intra-Abdominal InfectionsAcross US Hospitals
POSTER #1844 ERAVACYCLINE IS ACTIVE AGAINST CARBAPENEM Eravacycline is Active against Carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii Isolates in the FDA-CDC Antimicrobial Resistance Isolate Bank Panels Corey Fyfe, Gabrielle LeBlanc, Joyce A. Sutcliffe, Trudy H. Grossman PHARMACOKINETICS-PHARMACODYNAMICS OF EFFICACY FOR Brian D. VanScoy, B.S. Institute for Clinical Pharmacodynamics, Inc. 242 Broadway Schenectady, NY 12305 Telephone: (518) 631-8100 Fax:(518) 631-8199
POSTER # EFFICACY OF ERAVACYCLINE IN OBESE PATIENTS Efficacy of Eravacycline in Obese Patients: Pooled Analysis of IGNITE1 and IGNITE4 Allyson Fonte, Steven Kolkin, Kenneth Lawrence, SergeyIzmailyan
SUN-332 TP-6076, A FULLY SYNTHETIC TETRACYCLINE TP-6076, A Fully Synthetic Tetracycline Antibacterial Agent, Is Highly Potent against a Broad Range of Pathogens, including Carbapenem-resistant Enterobacteriaceae C MULTICENTER EVALUATION OF ERAVACYCLINE MIC RESULTS FOR Study Design: MicroScan Dried Gram Negative MIC panels were tested concurrently with a CLSI frozen broth microdilution reference panel atthree sites using
TETRAPHASE » WHO WE ARE Who We Are. Tetraphase is tackling the challenging clinical threat presented by antimicrobial resistance. Our multidisciplinary, collaborative team approach establishes a fully supportive work environment that helped us achieve our committed goal: to find technology-based solutions that ensure effective antibiotics are accessible to all who need them for the treatment of seriousinfections.
TETRAPHASE » TECHNOLOGY Until recently, technological challenges significantly limited the potential for developing tetracycline compounds. Our proprietary technology, developed at Harvard University and enhanced by Tetraphase, overcomes these challenges, making it possible to synthesize an unprecedented number of structurally diverse tetracycline-based drug candidates. TETRAPHASE » PIPELINE A fully synthetic tetracycline antibiotic in phase 1 clinical development. Potent activity in vitro against multidrug-resistant Gram-negative pathogens. Phase 1 multiple-ascending dose study complete. Received $4 million in funding from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to supportdevelopment.
TETRAPHASE » COMPLIANCE Communication. Tetraphase encourages an open dialogue of concerns from employees with regard to its business activities. All employees have access to report potential instances of fraud and abuse or other instances of potential violation of law, regulations, or company policy. These reports may be submitted through their management,compliance
TETRAPHASE » CULTURE Culture. Our culture is best characterized by collaboration and mutual support as we passionately pursue our work and life goals. We abide by the philosophy that our mission to fight antibiotic resistance is best achieved together — through collective thinking and problem-solving. TETRAPHASE » MEDIA RESOURCES Contact Us. Tetraphase Pharmaceuticals, Inc., a wholly owned subsidiary of La Jolla Pharmaceutical Company. 201 Jones Road, Suite 400, Waltham, MA 02451PRIVACY POLICY
Contact Us. Tetraphase Pharmaceuticals, Inc., a wholly owned subsidiary of La Jolla Pharmaceutical Company. 201 Jones Road, Suite 400, Waltham, MA 02451 PHARMACOKINETICS, SAFETY AND TOLERABILITY OF A NOVEL REVISED ABSTRACT Methods BACKGROUND Results Conclusions Printed by PHARMACOKINETICS, SAFETY AND TOLERABILITY OF A NOVEL FLUOROCYCLINE,TP-434,
POSTER 182 PHARMACOKINETICS OF TP-434 IN MOUSE, RAT, DOG Conclusions Abstract Results Pharmacokinetics of TP-434 in Mouse, Rat, Dog, Monkey and Chimpanzee M. RONN, N. DUNWOODY, J. SUTCLIFFE Tetraphase Pharmaceuticals, Watertown, MA USA POSTER 181 TP-434 IS METABOLICALLY STABLE AND HAS LOW Abstract TP-434 is Metabolically Stable and Has Low Potential for Drug-Drug Interactions D. CHRIST1 and J. SUTCLIFFE2 1SNC Partners LLC, Newark, DE and 2Tetraphase Pharmaceuticals Inc., Watertown, MA 50th Annual ICAAC 12-15 September, 2010 Boston, MA Acknowledgements TPHASE.COM - TETRAPHASEABOUTSCIENCEPRODUCTSPEOPLE AND CULTURECONTACTCOMPLIANCE A CRITICAL MISSION TO SAVE MILLIONS AT RISK. Tetraphase is fighting one of the most significant threats to humanity — antibiotic resistance — through the promise of our technology and the passion of our people. We are committed to making novel antibiotics accessible to all patients in need. Learn More. TETRAPHASE » OUR COMPANY Our Company. Committed to a Brighter Outlook. According to The Review on Antimicrobial Resistance (May 2016), by 2050, antimicrobial resistance is projected to kill more people than cancer and diabetes combined. At Tetraphase, the fight against antimicrobial resistance is TETRAPHASE » PIPELINE A fully synthetic tetracycline antibiotic in phase 1 clinical development. Potent activity in vitro against multidrug-resistant Gram-negative pathogens. Phase 1 multiple-ascending dose study complete. Received $4 million in funding from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to supportdevelopment.
TETRAPHASE » CONTACT US We are committed to providing the most current, accurate, and balanced scientific information on Tetraphase products in response to your unsolicited requests. Contact us directly: If in the US, call 1-833-7-XERAVA (1-833-793-7282), send an email to tphasemedinfo@ljpc.com, or complete the form below. If outside the US, send an email to medinfo AN EVALUATION OF EMPIRIC TREATMENT PATTERNS FOR ADULT An Evaluation of Empiric Treatment Patterns for Adult Patients with Community-Onset “Low-Risk” Complicated Intra-Abdominal InfectionsAcross US Hospitals
POSTER #1844 ERAVACYCLINE IS ACTIVE AGAINST CARBAPENEM Eravacycline is Active against Carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii Isolates in the FDA-CDC Antimicrobial Resistance Isolate Bank Panels Corey Fyfe, Gabrielle LeBlanc, Joyce A. Sutcliffe, Trudy H. Grossman PHARMACOKINETICS-PHARMACODYNAMICS OF EFFICACY FOR Brian D. VanScoy, B.S. Institute for Clinical Pharmacodynamics, Inc. 242 Broadway Schenectady, NY 12305 Telephone: (518) 631-8100 Fax:(518) 631-8199
POSTER # EFFICACY OF ERAVACYCLINE IN OBESE PATIENTS Efficacy of Eravacycline in Obese Patients: Pooled Analysis of IGNITE1 and IGNITE4 Allyson Fonte, Steven Kolkin, Kenneth Lawrence, SergeyIzmailyan
SUN-332 TP-6076, A FULLY SYNTHETIC TETRACYCLINE TP-6076, A Fully Synthetic Tetracycline Antibacterial Agent, Is Highly Potent against a Broad Range of Pathogens, including Carbapenem-resistant Enterobacteriaceae C MULTICENTER EVALUATION OF ERAVACYCLINE MIC RESULTS FOR Study Design: MicroScan Dried Gram Negative MIC panels were tested concurrently with a CLSI frozen broth microdilution reference panel atthree sites using
TPHASE.COM - TETRAPHASEABOUTSCIENCEPRODUCTSPEOPLE AND CULTURECONTACTCOMPLIANCE A CRITICAL MISSION TO SAVE MILLIONS AT RISK. Tetraphase is fighting one of the most significant threats to humanity — antibiotic resistance — through the promise of our technology and the passion of our people. We are committed to making novel antibiotics accessible to all patients in need. Learn More. TETRAPHASE » OUR COMPANY Our Company. Committed to a Brighter Outlook. According to The Review on Antimicrobial Resistance (May 2016), by 2050, antimicrobial resistance is projected to kill more people than cancer and diabetes combined. At Tetraphase, the fight against antimicrobial resistance is TETRAPHASE » PIPELINE A fully synthetic tetracycline antibiotic in phase 1 clinical development. Potent activity in vitro against multidrug-resistant Gram-negative pathogens. Phase 1 multiple-ascending dose study complete. Received $4 million in funding from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to supportdevelopment.
TETRAPHASE » CONTACT US We are committed to providing the most current, accurate, and balanced scientific information on Tetraphase products in response to your unsolicited requests. Contact us directly: If in the US, call 1-833-7-XERAVA (1-833-793-7282), send an email to tphasemedinfo@ljpc.com, or complete the form below. If outside the US, send an email to medinfo AN EVALUATION OF EMPIRIC TREATMENT PATTERNS FOR ADULT An Evaluation of Empiric Treatment Patterns for Adult Patients with Community-Onset “Low-Risk” Complicated Intra-Abdominal InfectionsAcross US Hospitals
POSTER #1844 ERAVACYCLINE IS ACTIVE AGAINST CARBAPENEM Eravacycline is Active against Carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii Isolates in the FDA-CDC Antimicrobial Resistance Isolate Bank Panels Corey Fyfe, Gabrielle LeBlanc, Joyce A. Sutcliffe, Trudy H. Grossman PHARMACOKINETICS-PHARMACODYNAMICS OF EFFICACY FOR Brian D. VanScoy, B.S. Institute for Clinical Pharmacodynamics, Inc. 242 Broadway Schenectady, NY 12305 Telephone: (518) 631-8100 Fax:(518) 631-8199
POSTER # EFFICACY OF ERAVACYCLINE IN OBESE PATIENTS Efficacy of Eravacycline in Obese Patients: Pooled Analysis of IGNITE1 and IGNITE4 Allyson Fonte, Steven Kolkin, Kenneth Lawrence, SergeyIzmailyan
SUN-332 TP-6076, A FULLY SYNTHETIC TETRACYCLINE TP-6076, A Fully Synthetic Tetracycline Antibacterial Agent, Is Highly Potent against a Broad Range of Pathogens, including Carbapenem-resistant Enterobacteriaceae C MULTICENTER EVALUATION OF ERAVACYCLINE MIC RESULTS FOR Study Design: MicroScan Dried Gram Negative MIC panels were tested concurrently with a CLSI frozen broth microdilution reference panel atthree sites using
TETRAPHASE » WHO WE ARE Who We Are. Tetraphase is tackling the challenging clinical threat presented by antimicrobial resistance. Our multidisciplinary, collaborative team approach establishes a fully supportive work environment that helped us achieve our committed goal: to find technology-based solutions that ensure effective antibiotics are accessible to all who need them for the treatment of seriousinfections.
TETRAPHASE » TECHNOLOGY Until recently, technological challenges significantly limited the potential for developing tetracycline compounds. Our proprietary technology, developed at Harvard University and enhanced by Tetraphase, overcomes these challenges, making it possible to synthesize an unprecedented number of structurally diverse tetracycline-based drug candidates. TETRAPHASE » COMPLIANCE Communication. Tetraphase encourages an open dialogue of concerns from employees with regard to its business activities. All employees have access to report potential instances of fraud and abuse or other instances of potential violation of law, regulations, or company policy. These reports may be submitted through their management,compliance
TETRAPHASE » CULTURE Culture. Our culture is best characterized by collaboration and mutual support as we passionately pursue our work and life goals. We abide by the philosophy that our mission to fight antibiotic resistance is best achieved together — through collective thinking and problem-solving. TETRAPHASE » MEDIA RESOURCES Contact Us. Tetraphase Pharmaceuticals, Inc., a wholly owned subsidiary of La Jolla Pharmaceutical Company. 201 Jones Road, Suite 400, Waltham, MA 02451PRIVACY POLICY
Contact Us. Tetraphase Pharmaceuticals, Inc., a wholly owned subsidiary of La Jolla Pharmaceutical Company. 201 Jones Road, Suite 400, Waltham, MA 02451 PHARMACOKINETICS, SAFETY AND TOLERABILITY OF A NOVEL REVISED ABSTRACT Methods BACKGROUND Results Conclusions Printed by PHARMACOKINETICS, SAFETY AND TOLERABILITY OF A NOVEL FLUOROCYCLINE,TP-434,
SUN-332 TP-6076, A FULLY SYNTHETIC TETRACYCLINE TP-6076, A Fully Synthetic Tetracycline Antibacterial Agent, Is Highly Potent against a Broad Range of Pathogens, including Carbapenem-resistant Enterobacteriaceae C POSTER 182 PHARMACOKINETICS OF TP-434 IN MOUSE, RAT, DOG Conclusions Abstract Results Pharmacokinetics of TP-434 in Mouse, Rat, Dog, Monkey and Chimpanzee M. RONN, N. DUNWOODY, J. SUTCLIFFE Tetraphase Pharmaceuticals, Watertown, MA USA POSTER 181 TP-434 IS METABOLICALLY STABLE AND HAS LOW Abstract TP-434 is Metabolically Stable and Has Low Potential for Drug-Drug Interactions D. CHRIST1 and J. SUTCLIFFE2 1SNC Partners LLC, Newark, DE and 2Tetraphase Pharmaceuticals Inc., Watertown, MA 50th Annual ICAAC 12-15 September, 2010 Boston, MA Acknowledgements* About
* Compliance
* Investors
* Overview
* Press Releases
* Stock Information
* Corporate Governance * Financials and Filings* Media Resources
* Events and Presentations* Science
* Overview
* Technology
* Publications
* Products
* XERAVA™ (eravacycline)* Pipeline
* People and Culture* Who We Are
* Join Our Team
* Culture
* Leadership
* Contact
* Contact and
Medical Information
A CRITICAL MISSION TO SAVE MILLIONS AT RISK Tetraphase is fighting one of the most significant threats to humanity — antibiotic resistance — through the promise of our technology and the passion of our people. We are committed to making novel antibiotics accessible to all patients in need.Learn More
NOVEL TECHNOLOGY HAS DELIVERED PROMISING PRODUCTS Our proprietary chemistry technology is yielding multiple tetracycline-based antibiotics with activity against some of the most challenging multidrug-resistant bacteria.SEE OUR SCIENCE
GET IN-DEPTH INVESTOR INFORMATIONJOIN OUR TEAM
If you have a passion for making a difference, find your fulfillment at Tetraphase.OPPORTUNITIES
PIPELINE PRODUCTS AVAILABLE FOR OUT-LICENSING Our products in development have the potential to change the course of antibiotic resistance for millions of patients at risk.PIPELINE
HOME
ABOUT
Our Company Message From Our CEOCompliance
INVESTORS
Overview Press ReleasesStock Information
Corporate
Governance Financials andFilings Media
Resources
Events and
Presentations
SCIENCE
Overview Technology
Publications
PRODUCTS
XERAVA™ Pipeline
PEOPLE
Who We Are Join Our TeamCulture
Leadership
CONTACT
Contact and Medical InformationCONTACT US
Tetraphase Pharmaceuticals, 480 Arsenal Way, Suite 100, Watertown, MA02472
Tel 617-715-3600 | Fax 617-926-3557 | CONTACT AND MEDICAL INFORMATIONFOLLOW US
|
SHARE
Forward-Looking Statements | Terms of Use| Privacy Policy
Copyright © 2020 Tetraphase Pharmaceuticals All rightsreserved.
To:
Please enter a valid email address.From:
Please enter a valid email address. Share information about TetraphaseCancel
Thank you!
Your email has been sent. This site uses cookies to give you the best possible experience. By browsing our website, you agree to our use of cookies. If you require further information and/or do not wish to have cookies placed when using the site, visit the Privacy Policypage.
More Information I accept THANK YOU FOR YOUR REQUEST. Someone will contact you shortly.OK
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0